Global Home - About us - Board of Directors

Board of Directors

The Board of Directors has adopted the Rules of Procedure for the Board of Directors which sets out the responsibilities of the Board of Directors in a number of areas. These include determining Xellia's overall strategy and actively contributing to developing the Group as a focused, sustainable, global specialty pharmaceutical company and supervising Xellia's Leadership Team in its decisions and operations.

  • Steen Riisgaard

    Chairman of the Board

  • Dr Andreas Rummelt

    Board Member

  • Barbara Purcell

    Board Member

  • Benny D Loft

    Board Member

  • Henrik Kjær Hansen

    Board Member

  • Julie McHugh

    Julie McHugh

    Board Member

  • Preben Haaning

    Board Member

Steen Riisgaard

Steen is the former President and CEO of Denmark based biotech company Novozymes A/S. He has also held senior level positions at Novo Nordisk A/S and Novo Industri A/S.

 

Other Board positions: Chairman of the Boards of ALKAbelló A/S and COWI Holding A/S. Vice Chairman of the Boards of the Novo Holdings A/S and the Villum Foundation. Member of the Boards of Novo Nordisk Foundation, Corbion, the University of Aarhus, Denmark, the Bird Protection Fund, Denmark and VKR Holding A/S.

 

Education: MSc in Microbiology, University of Copenhagen, Denmark.


Dr Andreas Rummelt

Andreas is a Partner and CEO of InterPharmaLink AG, Basle, Switzerland. His international career spans over twenty years in executive management positions at Novartis.

Other Board positions: Partner and CEO of InterPharmaLink AG. Member of the Boards of Alexion Pharmaceuticals, Inc., Alvogen, Leukocare AG and, Cypralis Ltd.

Education: MSc and Ph.D. in Pharmaceutical Sciences, University of ErlangenNuremberg, Germany.

 

Barbara Purcell

Barbara is President of the Diversified Portfolio at multinational specialty pharmaceutical company Bausch Health and is a member of its Executive Management team. She has spent the past 25 years working in the pharmaceutical industry mostly managing mature brands and generics. Most recently she was instrumental in building the generic division at Bausch Health as well as revitalizing several mature brand assets there. Previously, Barbara was Executive Director Global Sales and Marketing for Bausch + Lomb’s generics division, having also worked at Valeant, Novartis/ Sandoz and Zydus.

Education: MBA from Rutgers University and a BA from the University of Pittsburgh and qualified as a Certified Public Accountant (CPA).

Benny D Loft

Benny was EVP and CFO at Novozymes A/S until 2017, he has also worked on acquisitions and negotiations and played an active role in steering groups for numerous corporate functions including ethics, sustainability and business development.

 

Other Board positions: European Freeze Dry ApS.

Education: MSc in Accounting, Tax and Auditing, Copenhagen Business School, Denmark and State Authorized Public Accountant.


Henrik Kjær Hansen

Henrik joined Novo Holdings A/S in January 2017 as a Senior Director, Principal Investments, where he leads on the investment process and takes an active part in managing and developing the growing portfolio of investments. Prior to this, Henrik held a number of positions in the City of London. Most recently he was a Senior Vice President at Moelis & Co., focusing on healthcare buy and sell side M&A transactions. Previously he was with Deutsche Bank and ABN AMRO.

 

Other Board positions: Member of the Board of Directors of Orexo AB.

Education: BSc. in Business Administration and an MSc. in Applied Economic and Finance from the Copenhagen Business School, Denmark.

Julie McHugh

Julie McHugh has a track record that spans 34 years in the biopharmaceutical industry. Most recently, she was the COO at Endo Health Solutions, Inc., with responsibilities for both the specialty and generic pharmaceuticals businesses.

 

Other Board positions: Chairman of the Board of Visitors for the Smeal College of Business, Pennsylvania State University, Chairman of Ironwood Pharmaceuticals, Inc. Member of the Board of Directors of Aerie Pharmaceuticals, Inc., Lantheus Holding Inc. and Trevena Pharmaceuticals, Inc.

 

Education: BSc in Finance, Pennsylvania State University, USA and an MBA Administration in International Management, St. Joseph’s University, USA.


Julie McHugh

Preben Haaning

Preben Haaning, is currently working as Senior Vice President of Product Supply Biopharm, at Novo Nordisk, where he is responsible for large and small molecule drug substance and drug product manufacturing, supplying biologics for the treatment of rare blood and rare endocrine disorders.

 

He joined Novo Nordisk in 1999 as an Industrial Engineer. He has held various positions and most recently, from 2013 to 2019, as Senior Vice President he was responsible for an expanding an organisation of more than 6500 employees; supervising 5 manufacturing sites located in the US, Brazil, France, China and Denmark.


Prior to joining Novo Nordisk, Preben Haaning served as Platoon Leader for the United Nations Peace Keeping Forces in Cyprus, as well as First Lieutenant in the Royal Danish Army. 

 
Preben Haaning is elected to the Novo Nordisk Haemophilia Foundation Council.

 

Education: Graduated as an Industrial Engineer from the Danish Technical University and holds a diploma in Organisational Development from the Copenhagen Business School.